122 related articles for article (PubMed ID: 23987068)
1. [Anticancer activity of oxovanadium compounds].
Abakumova OIu; Podobed OV; Beliaeva NF; Tochilkin AI
Biomed Khim; 2013; 59(3):305-20. PubMed ID: 23987068
[TBL] [Abstract][Full Text] [Related]
2. Bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(IV) as a novel apoptosis-inducing anticancer agent.
Narla RK; Dong Y; D'Cruz OJ; Navara C; Uckun FM
Clin Cancer Res; 2000 Apr; 6(4):1546-56. PubMed ID: 10778988
[TBL] [Abstract][Full Text] [Related]
3. Selective hypoxia-cytotoxins based on vanadyl complexes with 3-aminoquinoxaline-2-carbonitrile-N1,N4-dioxide derivatives.
Vieites M; Noblía P; Torre MH; Cerecetto H; Laura Lavaggi M; Costa-Filho AJ; Azqueta A; de Cerain AL; Monge A; Parajón-Costa B; González M; Gambino D
J Inorg Biochem; 2006 Aug; 100(8):1358-67. PubMed ID: 16698084
[TBL] [Abstract][Full Text] [Related]
4. [Synthesis and hypoglycemic activity of bis(L-malato)oxovanadium(IV)].
Gorodetskiĭ VK; Tochilkin AI; Beliaeva NF; Kovel'man IR; Korovkin BF
Biomed Khim; 2011; 57(1):133-7. PubMed ID: 21516785
[TBL] [Abstract][Full Text] [Related]
5. A new halogenated antidiabetic vanadyl complex, bis(5-iodopicolinato)oxovanadium(IV): in vitro and in vivo insulinomimetic evaluations and metallokinetic analysis.
Takino T; Yasui H; Yoshitake A; Hamajima Y; Matsushita R; Takada J; Sakurai H
J Biol Inorg Chem; 2001 Feb; 6(2):133-42. PubMed ID: 11293406
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of cellular uptake, cytotoxicity and cellular ultrastructural effects of heteroleptic oxidovanadium(IV) complexes of salicylaldimines and polypyridyl ligands.
Scalese G; Correia I; Benítez J; Rostán S; Marques F; Mendes F; Matos AP; Costa Pessoa J; Gambino D
J Inorg Biochem; 2017 Jan; 166():162-172. PubMed ID: 27865131
[TBL] [Abstract][Full Text] [Related]
7. A new insulin-mimetic vanadyl complex, (N-pyridylmethylaspartate)oxovanadium(IV) with VO(N2O2) coordination mode, and evaluation of its effect on uptake of D-glucose by Ehrlich ascites tumour cells.
Tawa R; Uchida K; Taniyama J; Fujisawa Y; Fujimoto S; Nagaoka T; Kanamori K; Sakurai H
J Pharm Pharmacol; 1999 Feb; 51(2):119-24. PubMed ID: 10217308
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, X-ray structure, and anti-leukemic activity of oxovanadium(IV) complexes.
Dong Y; Narla RK; Sudbeck E; Uckun FM
J Inorg Biochem; 2000 Mar; 78(4):321-30. PubMed ID: 10857913
[TBL] [Abstract][Full Text] [Related]
9. Vanadyl complexes discriminate between neuroblastoma cells and primary neurons by inducing cell-specific apoptotic pathways.
Zhang Y; Wang L; Zeng K; Wang K; Yang X
J Inorg Biochem; 2018 Nov; 188():76-87. PubMed ID: 30121400
[TBL] [Abstract][Full Text] [Related]
10. Antioxidant, DNA cleavage, and cellular effects of silibinin and a new oxovanadium(IV)/silibinin complex.
Naso LG; Ferrer EG; Butenko N; Cavaco I; Lezama L; Rojo T; Etcheverry SB; Williams PA
J Biol Inorg Chem; 2011 Apr; 16(4):653-68. PubMed ID: 21399988
[TBL] [Abstract][Full Text] [Related]
11. An orally active antidiabetic vanadyl complex, bis(1-oxy-2-pyridinethiolato)oxovanadium(IV), with VO(S2O2) coordination mode; in vitro and in vivo evaluations in rats.
Sakurai H; Sano H; Takino T; Yasui H
J Inorg Biochem; 2000 May; 80(1-2):99-105. PubMed ID: 10885469
[TBL] [Abstract][Full Text] [Related]
12. Bis(oxalato)dioxovanadate(V) and bis(oxalato)oxoperoxo-vanadate(V) complexes: spectroscopic characterization and biological activity.
León IE; Etcheverry SB; Parajón-Costa BS; Baran EJ
Biol Trace Elem Res; 2013 Nov; 155(2):295-300. PubMed ID: 24026441
[TBL] [Abstract][Full Text] [Related]
13. Development of nanofunctionalized oxovanadium(IV) complex and its anticancer, antidiabetic, DNA cleavage and cell imaging studies.
Sunitha N; Isac Sobana Raj C; Sindhu Kumari B
Int J Pharm; 2023 Sep; 644():123339. PubMed ID: 37611853
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the glucose-lowering properties of vanadyl sulfate and bis(maltolato)oxovanadium(IV) following acute and chronic administration.
Yuen VG; Orvig C; McNeill JH
Can J Physiol Pharmacol; 1995 Jan; 73(1):55-64. PubMed ID: 7600453
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic effect of xyloglucan and oxovanadium (IV/V) xyloglucan complex in HepG2 cells.
Escaliante LADS; Busato B; Petkowicz CLO; Cadena SMSC; Noleto GR
Int J Biol Macromol; 2021 Aug; 185():40-48. PubMed ID: 34144065
[TBL] [Abstract][Full Text] [Related]
16. Structure-dependent metallokinetics of antidiabetic vanadyl-picolinate complexes in rats: studies on solution structure, insulinomimetic activity, and metallokinetics.
Yasui H; Tamura A; Takino T; Sakurai H
J Inorg Biochem; 2002 Jul; 91(1):327-38. PubMed ID: 12121792
[TBL] [Abstract][Full Text] [Related]
17. Apoptosis-inducing oxovanadium(IV) complexes of 1,10-phenanthroline against human ovarian cancer.
D'Cruz OJ; Dong Y; Uckun FM
Anticancer Drugs; 2000 Nov; 11(10):849-58. PubMed ID: 11142693
[TBL] [Abstract][Full Text] [Related]
18. Vanadyl-biguanide complexes as potential synergistic insulin mimics.
Woo LC; Yuen VG; Thompson KH; McNeill JH; Orvig C
J Inorg Biochem; 1999 Sep; 76(3-4):251-7. PubMed ID: 10605840
[TBL] [Abstract][Full Text] [Related]
19. Spermicidal activity of oxovanadium(IV) complexes of 1, 10-phenanthroline, 2,2'-bipyridyl, 5'-bromo-2'-hydroxyacetophenone and derivatives in humans.
D'Cruz OJ; Dong Y; Uckun FM
Biol Reprod; 1999 Feb; 60(2):435-44. PubMed ID: 9916012
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, immunomodulation and cytotoxic effects of vanadium (IV) complexes.
Ashiq U; Jamal RA; Mesaik MA; Mahroof-Tahir M; Shahid S; Khan KM
Med Chem; 2014 May; 10(3):287-99. PubMed ID: 23876231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
